News and Events

 

Stay up to date with news and events

EHDN 2026 Part 1: What’s next in the Huntington’s disease treatment pipeline?

From stopping CAG repeats from growing to finding new ways to tackle harmful huntingtin, scientists at the EHDN Clinical Research Congress 2026 shared exciting ideas…

Skyhawk’s drug trial takes flight in the US

Skyhawk’s FALCON-HD trial has dosed the first participants in the US with the drug, SKY-0515. The once-daily pill targets two drivers of HD, but does…

FDA sets May 2027 decision date on AMT-130 gene therapy for HD

The FDA has accepted uniQure’s application for AMT-130, an experimental gene therapy for Huntington’s disease, and set a May 2027 decision date. Here’s what this…

October 2026: This Month in Huntington’s Disease Research

From sticky thoughts and pigs that model HD to DNA repair and promising drug trial results, October brought fresh insights into HD. Here’s what you…

Turning down huntingtin: Alnylam’s brezosiran shows promising early result

An experimental treatment for HD developed by Alnylam has shown long-lasting huntingtin lowering after just one dose, with encouraging early safety data. A pivotal trial…

1 2 3 … 58